Tags : Opdivo

Biosimilars

Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

Shots: The company discloses two additional biosimilars in active development referencing Opdivo (nivolumab) and Keytruda (pembrolizumab). The biosimilars are in the advanced stages of pre-clinical development and are being co-developed by NeuClone and Serum Institute of India The disclosure demonstrates NeuClone’s ability to develop multiple biosimilars simultaneously through its NeuMAX platform Additionally, NeuClone and Serum […]Read More

Top 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]Read More

Regulatory

BMS’ Opdivo (nivolumab) Receives the US FDA’s Approval for Advanced

Shots: The US FDA’s approval is based on P-III ATTRACTION-3 study assessing Opdivo (240mg by IV infusion over 30min, q2w) vs taxane CT (docetaxel/paclitaxel) in patients with unresectable advanced, recurrent or ESCC, refractory/ intolerant to at least one prior fluoropyrimidine & platinum-based CT Opdivo is the first approved immunotherapy in this setting regardless of tumor […]Read More

Pharma

BMS Signs a Clinical Trial Collaboration with NeoImmune to Evaluate

Shots: NeoImmuneTech to sponsor the trial and BMS will supply Opdivo (nivolumab) for the use in the trial. Additionally, under Master Clinical Trial Collaboration Agreement, the first study will be focusing on gastric/GEJ/EAC cancers and the companies can evaluate additional combination trials in the future The goal of the collaboration is to evaluate preliminary anti-tumor […]Read More

Regulatory

BMS Reports the US FDA Acceptance of sBLA for Opdivo

Shots: The US FDA has accepted sBLA for the dual regimen as 1L treatment for metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations and has granted the PR status to the therapy The application is based on part 1 of P-III CheckMate -227 study results assessing Opdivo + Yervoy vs platinum-doublet […]Read More